New Two-Step transplant aims to cut deaths in blood cancer patients

NCT ID NCT05031897

Recruiting now Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemotherapy, and donor cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fludarabine, total-body irradiation, donor lymphocyte infusion, cyclophosphamide
What this could lead to: If successful, this could offer a safer transplant option for blood cancer patients, reducing the risk of death from treatment while still controlling the disease.
What could go wrong: This is a mid-stage trial with only 63 participants, so results may not apply to everyone. The approach may still carry risks of relapse or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera acute lymphoblastic leukemia acute myeloid leukemia adult T-cell leukemia/lymphoma aplastic anemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia essential thrombocythemia hematopoietic and lymphoid system neoplasm Hodgkins lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis myeloid neoplasm non-Hodgkin lymphoma plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA ADULT T-CELL LEUKEMIA/LYMPHOMA APLASTIC ANEMIA CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE CHRONIC MYELOMONOCYTIC LEUKEMIA ESSENTIAL THROMBOCYTHEMIA HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM HODGKIN LYMPHOMA MULTIPLE MYELOMA MYELODYSPLASTIC SYNDROME MYELOFIBROSIS MYELOID NEOPLASM NON-HODGKIN LYMPHOMA POLYCYTHEMIA VERA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITING

Philadephia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.